Plasma phosphorylated tau 217 and amyloid‐β 42/40 for amyloid risk in subgroups

Abstract

Background: Alzheimer’s disease (AD) is characterized by the accumulation of amyloid‐β (Aβ) pathology. Recently, plasma biomarkers, particularly p ‐tau217, have emerged as promising tools for early diagnosis and risk stratification.